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www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Mean age was 82(SD:6 yrs) & 50% were male.Median Euroscore was
17(IQR 10-22).Smoking (54%) and diabetes (20%) were the most common cardiac
risk factors.Access route of choice was femoral (94%). Medtronic Corevalve was used
most commonly (68%).Permanent pacing was required in 18% of patients & 9% had
at least one major complication.Event free survival was signiﬁcantly higher (92% vs.
65%) in the later time periods (GP 2 and 3: n¼128) compared to that in the “learning
curve” group (GP1: n¼60), (log rank p¼0.003),(graph 1).There was a 50% reduction
in index procedure hospital stay for the latest cohort compared to the ﬁrst two
cohorts (GP1 & 2 median ¼ 8 days, IQR 4-16 days),(GP3:median:4 days,IQR
3-9 days),(p¼0.002).
Conclusions: One year all-cause mortality has improved and hospital stay has reduced
over three consecutive time periods.The mortality reduction does not relate to patient
characteristics and may have been driven by acquired skills and experience of the
TAVI team and advances in valve designs
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Background: Transcatheter aortic valve implantation (TAVI) has become the stan-
dard intervention for elderly patients with aortic stenosis. Implantation of the valve
without pre-dilatation might have some advantages by reducing procedural steps and
thereby also the complication rate. This has been demonstrated for the antegrade
transapical access with the ballon-expandable Edwards SAPIEN XT valve. However,
the feasibility of TAVI with a balloon expandable device without predilatation using
the retrograde transfemoral route has not been evaluated yet.
Methods: Twenty six consecutive patients with stenosis of the native aortic valve
undergoing transfemoral TAVI with the Edwards Sapien XT prosthesis were enrolled
in this study.
Results: The procedure was successfully performed in all 26 patients - irrespective of
the aortic valve area and the extent of aortic valve calciﬁcation. At baseline mean
aortic valve area, mean AV gradient and median LVEF were 0.7  0.2 cm2, 36.0 
17.3 mmHg and 55.0% [IQR 35.0 – 60.0]; prior to discharge these values changed as
follows: 1.7  0.3 (p < 0.001), 9.8  6.1 mmHg (p < 0.001) and 57.5% [IQR 38.7 –
60.0] (p ¼ ns). Postdilatation due aortic regurgitation > 2 was required in 3 cases,
leading to aortic regurgitation < 2 in all patients. Of note, no periprocedural
neurological adverse events occurred.
Conclusions: Transfemoral aortic valve implantation without pre-dilatation using the
Edwards Sapien XT is feasible and safe.
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Background: The Vancouver Program initiated multidisciplinary and multimodality
risk stratiﬁcation to determine patients’ suitability for a transfemoral (TF) minimalist
peri-procedural approach, and implemented risk-stratiﬁed clinical pathways to facili-
tate discharge and reduce length of stay.
Methods: Standardized screening was implemented to conduct multimodality as-
sessments. Following multidisciplinary eligibility decision for TF TAVR by the Heart
Team, additional risk stratiﬁcation was discussed to determine individuals’ appro-
priateness for the peri-procedural “General Anaesthesia and Transesophageal Echo-
cardiography” (“GA/TEE”) and “Awake” (e.g., local anaesthesia) protocols, and the
planning requirements for standard (post-procedure day 3) and early (post-procedure
day 1-2) discharge protocols. Risk-stratiﬁed clinical pathways were developed to
support the patient cohorts.
Results: 144 consecutive patients were accepted for TF TAVR and assigned to risk-
stratiﬁed protocols. The mean age was 827 years, with the proportion of women
ranging from 37% to 42%, and mean STS risk scores between 6.3 and 7.1 in the 4
cohorts. The overall in-hospital outcomes included 2.1% mortality, 0% myocardial
infarction, 0.7% stroke, 2.1% life threatening bleeding, 0.7% new dialysis, and 4.2%
conduction disturbances requiring a new permanent pacemaker. The median length of
stay for all patients was 3 days (IQR 2-3), 2 days (IQR 1-3) in the Awake cohort and 2JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Va(IQR 1-2) in the Early Discharge cohort; 95.8% of patients were discharged home.
The 30-day all-cause hospital readmission rate was 11.1%, ranging from 7% and 8%
in the Awake and Early Discharge cohorts respectively, to 13% in the GA/TEE and
Regular Discharge cohorts; no new deaths occurred between discharge and 30 days.
Conclusions: Early experience with TAVR risk stratiﬁcation, individualized proce-
dure planning and tailored clinical pathways supported by multimodality screening
and multidisciplinary case selection and care results in excellent outcomes and opti-
mized length of stay.
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Background: Chronic kidney injury (CKD) seems to affect survival after TAVI, but
inconsistency in data exists. On the contrary, acute kidney injury (AKI) after TAVI is
prevalent and more clearly associated with mortality. However, an improvement in
serum creatinine is also prevalent after TAVI, possibly due to an improved renal blood
ﬂow. We analyzed the effects of an improved serum creatinine on prognosis in pa-
tients with and without CKD undergoing TAVI.
Methods: All patients undergoing TAVI in our centre for whom multiple serum
creatinine measurements after TAVI were available were prospectively enrolled from
June 2007 to December 2013. CKD was deﬁned as a glomerular ﬁltration rate <
60ml/min. Serum creatinine was measured before and after TAVI. The ratio of the
highest creatinine value after TAVI to before TAVI (CRR) was calculated. A CRR <
1.0 was deﬁned as an improvement, and a CRR 1.5 as AKI, further divided ac-
cording to the AKIN classiﬁcation.
Results: In total, TAVI was performed on 196 (mean age 82.16.4, male 42%, lo-
gistic EuroSCORE 26.916.6%) and 218 (mean age 79.97.5, male 45%, logistic
EuroSCORE 23.815.1%) patients with and without CKD, respectively. In the CKD
group, CRR was < 1.0, 1.0-1.5, and 1.5 in 98 (50.0%), 70 (35.7%) and 28 (14.3%)
of patients, respectively. In the group with normal renal function, CRR was < 1.0, 1.0-
1.5, and 1.5 in 85 (38.9%), 108 (49.5%) and 25 (11.5%) of patients, respectively.
AKI was an independent predictor for early and late mortality. An improvement of
renal function was a negative independent predictor for 2-year mortality in patients
with CKD (HR 0.28, 95% CI 0.15 to 0.51, p< 0.001) but not for patients without
CKD (HR 0.70, 95% CI 0.41 to 1.20, p¼0.19).
Conclusions: The occurrence of AKI is an independent predictor for mortality after
TAVI in patients with and without CKD. However, an improved renal function after
TAVI predicts long-term survival only for patients with prior CKD.
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Background: The aim of this study was to compare the outcomes of transcatheter
aortic valve implantation (TAVI) with the Medtronic CoreValve Revalvivng System
(MCV) with or without preparatory balloon aortic valvuloplasty (PBAV).
Methods: From November 2007 to September 2013 all patients treated with MCV
were included in this analysis. Patients were divided in 2 groups: those where PBAV
was performed and those where MCV was directly implanted. PBAV was performed
according to operator descretion, after consideration of patient anatomical character-
istics. Outcomes were assessed according to valvular academic research consortium
(VARC-2) criteria at 30 days and 1 year.
Results: Of 538 patients that underwent TAVI in our center, 206 were treated with a
MCV via one of the available access routes. Of those, 133 underwent PBAV, while 73
direct valve implantation. Baseline characteristics between the 2 groups were similar.
At 30 days there were no signiﬁcant differences in all-cause and cardiovascular
mortality (3% vs. 5.5%, p ¼ 0.380; and 1.5% vs. 5.5%, p ¼ 0.105; respectively). A
trend for a higher incidence of cardiac tamponade (2.4% vs. 7.8%; p ¼ 0.078) and a
signiﬁcantly higher rate of at least moderate peri-prosthesic aortic regurgitation
(PPAR) requiring valvular balloon post-dilation (VBPD; 35.6% vs. 49.3%, p¼ 0.056)
was noted amongst patients where PBAV was not performed. Conversely patients
who underwent PBAV had more AKI (32.3% vs. 19.4%; p ¼ 0.049). No signiﬁcantlvular disease - Aortic: TAVR B217
